MAP3K8/Tpl2/COT Antibody Blocking Peptide

• Reactivity: Hu
• Applications: AC
• Concentration: 2.5 mg/ml

MAP3K8/Tpl2/COT Antibody Blocking Peptide Summary

• Description: A MAP3K8/Tpl2/COT antibody blocking peptide.
• Protein/Peptide Type: Antibody Blocking Peptide
• Gene: MAP3K8
• Purity: >85%, by HPLC

Applications/Dilutions

• Dilutions:
  • Antibody Competition
• Application Notes: This peptide is useful as a blocking peptide for NBP1-62178. For further blocking peptide related protocol, click here.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: Sodium Bicarbonate buffer, pH 8.00 containing up to 10% DMSO
• Concentration: 2.5 mg/ml
• Purity: >85%, by HPLC

Alternate Names for MAP3K8/Tpl2/COT Antibody Blocking Peptide

• Cancer Osaka thyroid oncogene
• c-COT
• cot (cancer Osaka thyroid) oncogene
• COT
• COTMEKK8
• EC 2.7.11.25
• EST
• ESTF
• ESTFLJ10486
• Ewing sarcoma transformant
• MAP3K8
• mitogen-activated protein kinase kinase kinase 8
• Proto-oncogene c-Cot
• proto-oncogene serine/threoine protein kinase
• Serine/threonine-protein kinase cot
• TPL2
• Tpl-2
• Tumor progression locus 2
• tumor progression locus-2

Background

Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Bioinformatics

• Gene Symbol: MAP3K8